VANCOUVER, British Columbia, Aug. 25, 2005 (PRIMEZONE) -- Dr. John Todd, president and CEO of ProtoKinetix, Inc. (OTCBB:PKTX) announces today the results of the in-vitro effect of their synthetic antifreeze glycoprotein (AFGP) on embryonic human fibroblast skin cells. Prior work has confirmed that our synthetic AFGP is able to preserve human kidney cells, red blood cells, and platelets as well as rat cardiac cells and tissue. Now, using 5 mgm per ml of monomeric AFGP, the results are very positive, in that the human fibroblast skin cells clearly show a better survivability at all temperatures from 22 degrees C to minus 3 degrees C. At 3 degrees C after 30 hours, 64 percent of the cells in the AFGP solution were alive versus 15 percent of the cells in the control solution (with no AFGP). These results are a very strong indication that ProtoKinetix's AFGP can be used as an additive to help preserve skin cells.
The work was conducted for ProtoKinetix by ProteoCell Biotechnologies, Inc. of Montreal. Dr. Samer Hussein, lead scientist for ProteoCell states, "clearly we are preserving skin cells." Dr. Hussein further states that "this AFGP molecule could have major implications for the cosmetic skin care industry." This study is ongoing as ProtoKinetix continues to investigate the effectiveness of AFGP in protecting skin cells subjected to a variety of stresses.
About ProtoKinetix
ProtoKinetix, Inc. (PKTX) is a scientific development company whose mission is the advancement of human health care. The company's first entry into the commercial marketplace will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry, molecular biology and medicine in order to fast track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future, and accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the company. For a description of additional risks and uncertainties, please refer to the company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors, Dr. John Todd, President